Literature DB >> 6652234

Dipyridamole and intravenous deoxycytidine therapy in a patient with adenosine deaminase deficiency.

A J Ammann, M J Cowan, D W Martin, D W Wara.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652234

Source DB:  PubMed          Journal:  Birth Defects Orig Artic Ser        ISSN: 0547-6844


× No keyword cloud information.
  5 in total

1.  SLGT2 Inhibitor Rescues Myelopoiesis in G6PC3 Deficiency.

Authors:  Prashant Hiwarkar; Umair Bargir; Ambreen Pandrowala; Minnie Bodhanwala; Naresh Thakker; Prasad Taur; Manisha Madkaikar; Mukesh Desai
Journal:  J Clin Immunol       Date:  2022-07-15       Impact factor: 8.542

2.  Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype.

Authors:  I Santisteban; F X Arredondo-Vega; S Kelly; A Mary; A Fischer; D S Hummell; A Lawton; R U Sorensen; E R Stiehm; L Uribe
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

3.  Genetic heterogeneity in adenosine deaminase (ADA) deficiency: five different mutations in five new patients with partial ADA deficiency.

Authors:  R Hirschhorn; A Ellenbogen
Journal:  Am J Hum Genet       Date:  1986-01       Impact factor: 11.025

4.  Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency.

Authors:  L D Notarangelo; G Stoppoloni; R Toraldo; E Mazzolari; A Coletta; P Airò; C Bordignon; A G Ugazio
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

5.  Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency.

Authors:  G Morgan; R J Levinsky; K Hugh-Jones; L D Fairbanks; G S Morris; H A Simmonds
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.